• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: THERAKOS, INC. / MALLINCKRODT HOSPITAL PRODUCTS, INC. CELLEX SYSTEM; SYSTEM, PHOTOPHERESIS, EXTRACOPOREAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

THERAKOS, INC. / MALLINCKRODT HOSPITAL PRODUCTS, INC. CELLEX SYSTEM; SYSTEM, PHOTOPHERESIS, EXTRACOPOREAL Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Pulmonary Embolism (1498)
Event Date 06/21/2019
Event Type  Injury  
Event Description
Pulmonary emboli (pe) was diagnosed in a pt who had received 18 extracorporeal photopheresis (ecp) treatments via the cellex system.Bronchiolitis obliterans syndrome (bos).The pt received is 18th ecp treatment on (b)(6) 2019.The pe event occurred on (b)(6) 2019.The pi reported no relationship.The pt was hospitalized for the event.The pt was initially evaluated in clinic for increased shortness of breath and admitted to the hosp.Ct chest without contrast (b)(6) 2019: postoperative change from bilateral lung transplant, eccentric nonocclusive filling defect within the right main pulmonary artery proximal to the pulmonary artery anastomosis measuring 2.9 x 1.6 cm.Findings are consistent with thrombus; however, the chronicity is uncertain and could be acute or chronic; new bilateral groundglass and patchy consolidative opacities most severely affecting the left upper lobe.Findings favor multifocal infection; diffuse mosaic attenuation of the lungs most commonly associated with air trapping / constrictive bronchiolitis; new 4mm right upper lobe nodule may be inflammatory, however recommend 3 month f/u to ensure stability; aortic and coronary artery atherosclerosis.Stable mild dilation of the mid ascending aorta measuring 4 cm.The main pulmonary artery is dilated; pneumobilia which is new from the prior correlate with interval interventions.Treated with heparin drip and changed to oral anticoagulation.The pt received 18 ecp treatments for bronchiolitis obiterons syndrome: (b)(6) 2019, (b)(6) 2019, (b)(6) 2019, (b)(6) 2019.Following the pe event the pt resumed ecp treatments and completed 24 total.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CELLEX SYSTEM
Type of Device
SYSTEM, PHOTOPHERESIS, EXTRACOPOREAL
Manufacturer (Section D)
THERAKOS, INC. / MALLINCKRODT HOSPITAL PRODUCTS, INC.
MDR Report Key9818142
MDR Text Key183352079
Report NumberMW5093661
Device Sequence Number1
Product Code LNR
Combination Product (y/n)N
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Nurse
Type of Report Initial
Report Date 03/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received03/10/2020
Was Device Evaluated by Manufacturer? No Information
Type of Device Usage N
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Other;
Patient Age66 YR
Patient Weight86
-
-